Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Biomea Fusion, Inc. (BMEA : NSDQ)

• Company Description    Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $1.25 Daily Weekly Monthly 20 Day Moving Average: 862,374 shares Shares Outstanding: 72.30 (millions) Market Capitalization: $90.37 (millions) Beta: -0.31 52 Week High: $2.99 52 Week Low: $0.87 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.63% 0.88% 12 Week -8.09% -10.61% Year To Date 0.81% -6.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1599 INDUSTRIAL ROAD - SAN CARLOS,CA 94070 USA ph: 650-980-9099 fax: - ir@biomeafusion.com http://www.biomeafusion.com

• General Corporate Information    Officers Michael J.M. Hitchcock - Interim Chief Executive Officer; Director Rainer Erdtmann - Chief Operating Officer; Director Eric Aguiar - Director Julianne Averill - Director Sumita Ray - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09077A106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 72.30 Most Recent Split Date: (:1) Beta: -0.31 Market Capitalization: $90.37 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.83 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 78.75% vs. Previous Quarter: 73.44% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -265.37 12/31/25 - -305.60 ROA 06/30/26 - - 03/31/26 - -103.96 12/31/25 - -128.09 Current Ratio 06/30/26 - - 03/31/26 - 4.98 12/31/25 - 5.23 Quick Ratio 06/30/26 - - 03/31/26 - 4.98 12/31/25 - 5.23 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 0.26 12/31/25 - 0.42 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©